Ex Vivo Study of hAMSC Secretome in Inflammatory Bowel Disease: Effects on Inflammation and Fibrosis (TARGET) | MicrobiomeTrials← Back to trialsNCT07721207
Ex Vivo Study of hAMSC Secretome in Inflammatory Bowel Disease: Effects on Inflammation and Fibrosis (TARGET)
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-11-01Est. Completion: 2027-11-01
Enrollment target: 40 participants Other microbiome trials you might be interested in
Atrophic Gastritis
Chronic atrophic gastritis (CAG) is a common and frequently-occurring disease, characterized by atrophy of gastric mucos…
Hong Kong, Hong KongCompleted Nov 22, 2024
DysphagiaEosinophilic Esophagitis
Background:
Eosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the…
Bethesda, United StatesEst. completion Aug 31, 2027
WITHDRAWN
Fistula in AnoCrohn Disease
Crohn's disease is a chronic inflammatory condition that can affect any part of the bowel which can be controlled by a c…
Multiple LocationsCompleted Jun 11, 2026